Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relative age effect

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    642 result(s) found for: Relative age effect. Displaying page 7 of 33.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2008-008720-33 Sponsor Protocol Number: PDP007 Start Date*: 2009-06-08
    Sponsor Name:Cliniques Universitaires St Luc
    Full Title: A one year, open, prospective study on the role of quarterly intravitreal injections of Lucentis 0,5 mg (ranibizumab) in preventing of delaying progression of radiation retinopathy in eyes treated ...
    Medical condition: Radiation retinopathy in eyes treated with Iodine 125 plaque radiotherapy for posterior uveal melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064714 Radiation retinopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001090-16 Sponsor Protocol Number: 2017003001 Start Date*: 2017-09-22
    Sponsor Name:University Medical Center Groningen
    Full Title: A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial
    Medical condition: Chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001071-33 Sponsor Protocol Number: Birr20201 Start Date*: 2022-02-03
    Sponsor Name:BirrBeheerBV
    Full Title: Role of the intestine on osteoarthritis of the hand and the effect of Sustained Release Calcium Butyrate.
    Medical condition: Osteoarthritis of the hand
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004851-30 Sponsor Protocol Number: GABA-1 Start Date*: 2016-08-01
    Sponsor Name:PHARM – Pharmaceutical Research Management srl
    Full Title: Randomized, double-blind, double-dummy, active controlled, multicentre, non-inferiority phase-III study to compare the pharmacokinetic, efficacy and safety of gabapentin liquid formulation to trama...
    Medical condition: Chronic pain of neuropathic or mixed origin
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10054095 Neuropathic pain LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Completed) FR (Ongoing) GR (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001654-65 Sponsor Protocol Number: PDY16967 Start Date*: 2021-11-30
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: A Phase 2a, open label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD)
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    26.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000923-37 Sponsor Protocol Number: TriComB Start Date*: 2021-08-04
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: A phase 1/2 study exploring the safety and activity of Trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients.
    Medical condition: metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004775-39 Sponsor Protocol Number: C2541013 Start Date*: 2020-08-21
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINI...
    Medical condition: BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGE 2 OR 3
    Disease: Version SOC Term Classification Code Term Level
    27.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis LLT
    20.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-005845-18 Sponsor Protocol Number: D7990C00004 Start Date*: 2021-06-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Parallel, Double-Blind, Placebo-Controlled Phase 2b Study to Assess the Safety, Tolerability and Efficacy of AZD8233 Treatment in Participants with Hyperlipidaemia
    Medical condition: Hyperlipidaemia, evaluation of low-density lipoprotein cholesterol reduction and safety of AZD8233 vs. placebo
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10062060 Hyperlipidaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DK (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-001695-19 Sponsor Protocol Number: FER-CARS-05 Start Date*: 2011-12-22
    Sponsor Name:Vifor (International) Inc.
    Full Title: A Randomised, Double-blind Controlled Phase 4 Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose with Placebo in Patients with Chronic Heart Failure and Iron Deficiency
    Medical condition: Iron deficiency in patients with chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10008908 Chronic heart failure LLT
    14.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) DE (Completed) SE (Completed) GB (Completed) IE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002580-13 Sponsor Protocol Number: LPA111834 Start Date*: 2009-05-05
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomised, double-blind, placebo-controlled, 2-period cross-over study to evaluate the effect of treatment with GSK2190915 on the allergen-induced asthmatic response in subjects with mild asthma
    Medical condition: Mild asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000913-33 Sponsor Protocol Number: DIAB1 Start Date*: 2020-06-02
    Sponsor Name:University of gothenburg
    Full Title: Semaglutide and dapagliflozin in diabetic patients with different pathophysiology
    Medical condition: Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003384-51 Sponsor Protocol Number: 20060341 Start Date*: 2007-12-11
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination with Bevacizumab and Paclitaxel or AMG386 plus Paclitaxel as First-Line Therapy in Subjects with Her2-Negative, Metas...
    Medical condition: Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) GB (Completed) AT (Completed) BE (Completed) DK (Completed) FI (Completed) NL (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003516-31 Sponsor Protocol Number: NEOPACHI-001 Start Date*: 2012-11-29
    Sponsor Name:CUB Erasme Hospital
    Full Title: Evaluation of tumoral perfusion modification by dynamic imaging after neoadjuvant chemotherapy combining gemcitabine and a Hedgehog inhibitor (Vismodegib) in patients with resectable pancreatic ade...
    Medical condition: Potentially resectable pancreatic ductal adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004539-18 Sponsor Protocol Number: PGCN-001 Start Date*: 2018-08-27
    Sponsor Name:Prolong Pharmaceuticals, LLC
    Full Title: A Phase 2, Open-Label, Multicenter, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF–Rho™ in Patients with Chronic Neutropenia
    Medical condition: Chronic neutropenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000013471 10066702 Chronic neutropenia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005958-23 Sponsor Protocol Number: Y-47-52120-128 Start Date*: 2008-03-03
    Sponsor Name:Ipsen Group, SCRAS Institut Henri Beaufour
    Full Title: A Phase II, Randomised, Double-Blind Study to Compare the Safety and Efficacy of One Treatment Cycle of Clostridium Botulinum Type A Toxin (50 Units) When Reconstituted from Either a 125 Unit or a ...
    Medical condition: Moderate to severe vertical glabellar lines.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052609 Glabellar frown lines LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004132-22 Sponsor Protocol Number: NPH-01 Start Date*: 2021-01-20
    Sponsor Name:Uppsala University Hospital
    Full Title: Double-blind randomized acetazolamide trial in normal pressure hydrocephalus
    Medical condition: Normal pressure hydrocephalus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10020510 Hydrocephalus acquired LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000521-38 Sponsor Protocol Number: EORTC-08112 Start Date*: 2017-06-30
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Nintedanib as maintenance treatment of malignant pleural mesothelioma (NEMO): a double-blind randomized phase II study of the EORTC Lung Cancer Group
    Medical condition: Malignant pleural mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035606 Pleural mesothelioma malignant localised LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-016366-88 Sponsor Protocol Number: 28431754DIA3002 Start Date*: 2010-05-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type ...
    Medical condition: type 2 diabetes mellitus (T2DM) with inadequate glycemic control on combination therapy with metformin and a sulphonylurea (SU)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (Completed) FR (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-005443-14 Sponsor Protocol Number: NGAM-08 Start Date*: 2017-04-28
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: Prospective, double-blind, randomized, multicenter phase III study evaluating efficacy and safety of three different dosages of NewGam in patients with chronic inflammatory demyelinating poly(radic...
    Medical condition: Chronic Inflammatory Demyelinating Poly(radiculo)-neuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Prematurely Ended) SE (Prematurely Ended) HU (Completed) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-002560-16 Sponsor Protocol Number: 747-303 Start Date*: 2015-12-10
    Sponsor Name:Intercept Pharmaceuticals Inc.
    Full Title: A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
    Medical condition: Nonalcoholic steatohepatitis
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004871 10029530 Non-alcoholic fatty liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Completed) SE (Completed) BE (Completed) DK (Completed) ES (Completed) FI (Completed) PT (Prematurely Ended) HU (Completed) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 17:05:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA